Webinar Overview Date: Tuesday, Nov 14, 2017
Time: 10 AM PT / 1PM ET
Duration: 1 hour
Managing wound complications such as skin and soft tissue infections is a well-known challenge for clinicians. Multiple interventions are typically required for optimal outcomes, and initiating the appropriate antimicrobial therapy for SSTIs within the first 48 hours is key. This program highlights the burden of infected wounds on patients and the healthcare system, explains the significance of antibiotic failure, particularly early in the course of therapy, and describes how DxWound provides a rapid, comprehensive assessment of the wound microbial environment, thus helping clinicians rapidly target antimicrobial therapy.
Objectives: Upon completion of this session participants will be able to:
Recognize the burden of infected wounds on patients and the healthcare system
Explain the significance of antibiotic failure, particularly early in the course of therapy
Describe how DxWound provides a rapid, comprehensive assessment of the wound microbial environment
Discuss how DxWound may help clinicians rapidly target antimicrobial therapy
Sandy Estrada Pharm.D., BCPS (AQID) Lee Health
Brandon Adkins Pharm.D., MS, CSPI Millennium Health
The study is the largest of its kind that examines BCHE genetic variants
SAN DIEGO – Nov. 2, 2017 – A new study explored the variations of the BCHE gene in ethnic groups in the United States. Patients with severe BChE deficiency have an increased risk of prolonged neuromuscular blockade and respiratory depression in response to succinylcholine, a neuromuscular blocking agent commonly used during surgery. A genetic test can predict the likelihood that a patient will have a BChE deficiency based on variations in the BCHE gene. In the study of 13,301 patients, 8 percent were predicted to have moderate BChE deficiency while 0.06 percent were predicted to have severe BChE deficiency. The study was conducted by CogenDx, the genetics brand of Millennium Health, LLC.
As it often the case with disruptive innovations, the pace of technological development may often outstrip the clinician end-users understanding of how to use this type of diagnostic information. For wound clinicians interested in learning how the recent genomic advances may benefit their patients, it is important to understand both the advantages and disadvantages these tests offer. When assessing the microbial jungle of the wound, your best bet is to know your tour guide.
DxWound uses advanced genomic technology to offer a consolidated solution for wound care providers
SAN DIEGO – Oct. 3, 2017 – CogenDx, the genetics brand of Millennium Health, LLC, announced today the launch of its newest test offering, DxWound. The test uses DNA-based technology to provide accurate, sensitive detection of an array of microbes, including aerobic and anaerobic bacteria, fungi, plus antibiotic resistance genes. Results from the tests equip clinicians to rapidly and accurately identify potential pathogens causing infections and select antibiotics with greater likelihood for efficacy.
The abstract and poster will be displayed at PAINWeek in Las Vegas from Sept. 5-9 and will be discussed in a presentation on Sept. 8.
SAN DIEGO – Sept. 6, 2017 – A new study examined the frequency of day surgery patients who were treated with multiple injectable opioids, and analyzed the economic burden associated with this treatment practice. The findings reveal that of 63,392 patients, 45 percent were treated with two or more different injectable opioids on the day of surgery. These patients were more likely to be readmitted within 30 days of surgery and had average hospital charges that were higher by $1,458 compared similar patients who weren’t treated in the same manner. The study was conducted by CogenDx, which offers genetic testing to identify how a patients’ genetic profile may impact his or her response to certain medications.
In 2016, researchers overturned the long-standing belief that a person’s microbiome – the sum total of microbes living in and on our bodies – outnumbered human cells 10 to 1.1 Instead, it’s closer to a 1 to 1 ratio, they estimated. While it’s heartening to learn that we’re not outnumbered in our own skin, the tremendous ubiquity of bacteria, both on us and around us, underscores the notion that it’s really a bacterial world and we’re just living in it.
Patients with postoperative respiratory depression could see greater economic consequences compared with patients without the condition, suggests a recent study by CogenDx, the genetics brand of Millennium Health.
A poster of this study will be displayed at the International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting on Tuesday, May 23 from 8 am to 2 pm.
SAN DIEGO – May 23, 2017 – An abstract and poster presented by CogenDx, which offers genetic testing to identify how a patients’ genetic profile may impact his or her response to certain medications, details the results from a recent study into the occurrence of postoperative respiratory depression after inpatient surgery. The study of 17,727 patients found that 4 percent of patients undergoing inpatient surgery experienced postoperative respiratory depression, and the average hospital charges for these patients were $9,180 higher than similar patients who did not experience such respiratory depression.
The abstract and poster will be displayed at the International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting on Tuesday, May 23.
SAN DIEGO – May 22, 2017 – A new study examined the occurrence of patients undergoing treatment with multiple opioids for postoperative pain following inpatient surgery, and calculates the associated hospital charges. The findings reveal that of 17,727 patients, 33 percent were treated with three or more different injectable opioids on the day of surgery. The average hospital charges for these patients were $2,559 higher compared to similar patients who weren’t treated for pain in a similar manner. The study was conducted by CogenDx, which offers genetic testing to identify how a patients’ genetic profile may impact his or her response to certain medications.
CogenDx will present the study at the Annual Clinical Genetics Meeting of the American College of Medical Genetics on March 23, 2017
SAN DIEGO – March 23, 2017 – A new genetic test has been discovered that allows for fast and accurate identification of individuals who carry HLA-B*15:02 and who are therefore at risk for a rare yet potentially deadly side effect of certain medications used to treat seizures and bipolar disorder. The gene HLA-B*15:02 is strongly associated with life-threatening severe skin hypersensitivity reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis in patients treated with carbamazepine and related medications such as lamotrigine and phenytoin.
The CogenDx logo is a service mark or registered service mark of Millennium Health, LLC or its subsidiaries in the United States and other Countries. All other trademarks used herein are the property of their respective owners. These clinical laboratory developed tests (LDTs) were developed and their performance characteristics determined by Millennium Health, LLC and have not been cleared or approved by the US Food and Drug Administration (FDA). These LDTs are clinical tests and their results should be used with other clinical observations and diagnostic findings for patient case management. Millennium Health, LLC maintains certification in accordance with Clinical Laboratory Improvement Amendments of 1988 and is accredited by the College of American Pathologists.